AGP Limited · PSX:AGP

AGP — Investor Presentation (August 2019)

15 slides from AGP's investor presentation, Aug 8, 2019

  1. Slide 1: AGP Limited Corporate Briefing Session

    AGP Limited Corporate Briefing Session 08th August 2019

  2. Slide 2: Table of Contents

    Table of Contents 1. Financial Performance Jan-Jun-19 2. Analysis of Variances in Half Year Profit & Loss 3. Financial Performance 2016-2019 4. Corporate Information & Structural Changes 5. Pharma Sector Overview 6. Regulatory and Pricing Environment and Updates 7. Imports from India in Recent Times

  3. Slide 3: AGP Limited – Financial Performance Jan-Jun-19

    AGP Limited – Financial Performance Jan-Jun-19  AGP limited (“AGPL”) posted net profit of PKR 743 Mn for the period of Jan-Jun 2019 translating into EPS of PKR 2.65 10.2% 23% 22%  Interim dividend of PKR 1.25/share  Revenue grew by 10.2% in 1st half Revenue Net Profit Return on 2019. Growth Margi

  4. Slide 4: Analysis of Variances - Profit & Loss Jan-Jun-19

    Analysis of Variances - Profit & Loss Jan-Jun-19 (PKR in Mn) Jan-Jun Jan-Jun Var % Remarks 2019 2018  With an overall growth of 10.2%, the growth in Q1 was 4% and 19% in Q2. Sales 10%  Ignoring non-recurring sales (of PKLI in 2018 and similar 3,159.3 2,866.3 tender sales in 2019) the sales grew by

  5. Slide 5: Financial Performance

    Financial Performance Amount in PKR '000 Dec-16 (12M) Dec-17 (12M) Dec-18 (12M) Jun-19 (6M) Income Statement Revenue 4,205,750 4,724,990 5,382,055 3,159,327 Gross Profit 2,460,112 2,874,392 3,040,649 EBITDA 1,634,426 1,718,688 1,724,078 1,836,699 Operating Profit 1,528,879 1,610,235 1,625,558 Profit

  6. Slide 6: Rigix – Billion Rupee Brand

    Rigix – Billion Rupee Brand 1066 mn 927 mn of 19% 760 mn CAGR 633 mn 522 mn 415 mn 381 mn 269 mn 301 mn 219 mn 245 mn 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2Q-2019 (MAT Basis) 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Price Growth 0.0% 0.0% 0.0% 0.0% 5.5% 10.4% 0.0% 1.1% 3.2% 13.

  7. Slide 7: AGP – Corporate Information

    AGP – Corporate Information AGP Limited - Pattern of Shareholding in Board of Directors Jun-19 Tariq Moinuddin Khan Chairman AitkenStuart Pakistan (Pvt.) Limited Nusrat Munshi CEO & Executive Director 50.53% Kamran Nishat Director (Muller & Phipps) Tariq Moinuddin Khan Mahmud Yar Hiraj Director (Bal

  8. Slide 8: AGP Ownership Structure

    AGP Ownership Structure  For the purposes of better organizational management and pooling of business risks, scheme for rearrangement, restructuring and reorganization of OBS group was undertaken.  Under the Scheme of Arrangement sanctioned by the Court, shares of AGP Limited held with OBS Pakista

  9. Slide 9: Sector Overview

    Sector Overview  Compound Annual Growth Rate (CAGR) of total Market over last 5 years (Jun-19 vs Jun-15) in PKR is 13.1%  Total 12 months Pakistan Pharma Market:  Total revenue in PKR – 423 Billion  Share of local manufacturers in Pakistan is 69%  Total growth June-2019 MAT Basis (PKR) – 13.23%

  10. Slide 10: Major Industry Players

    Major Industry Players The top 10 corporates all have annual sales more than PKR 10 Bn and collectively have a ~39% share of the industry’s revenues. Top 25 corporates, in terms of revenue and growth rate, are shown below in the bar diagrams. They contribute around 62.6% of the total market share

  11. Slide 11: Regulatory and Pricing Environment and Updates

    Regulatory and Pricing Environment and Updates  Pharma Industry operates in a heavily regulated environment, stringent and closely monitored and administered by Drug Regulatory Authority of Pakistan (DRAP).  New molecules can take up to 12-18 months to register and generics take up to 3 years. Slo

  12. Slide 12: Imports from India in Recent Times

    Imports from India in Recent Times In light of the emergent strained relationship with India, AGP at the beginning of the current year undertook a detailed analysis of its supplies from India. Findings are as under: Raw Materials:  Currently, 24% of raw materials (in value) are imported from India

  13. Slide 13: Challenges & Future Outlook

    Challenges & Future Outlook  The Pak Rupee has seen a devaluation of • Spending on pharmaceutical drugs over 15.6% since December 2018 while remains low compared to our key interest rates are increased by 325 International counterparts and the basis points since January 2019. We regional average, p

  14. Slide 14: Challenges & Future Outlook - Nutraceutical Plant

    Challenges & Future Outlook - Nutraceutical Plant  Nutraceuticals is a growing segment with several players entering the market in the recent past. It is a relatively less regulated segment with market forces determining product pricing  With 2 years of experience in this segment, AGP has witnesse

  15. Slide 15: Q&A Thank you

    Q&A Thank you

AGP — Investor Presentation (August 2019) on 6ix